ClinVar Miner

Submissions for variant NM_000033.4(ABCD1):c.1526A>G (p.Asn509Ser)

gnomAD frequency: 0.00002  dbSNP: rs782158792
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000534849 SCV000629990 pathogenic Adrenoleukodystrophy 2024-01-03 criteria provided, single submitter clinical testing This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 509 of the ABCD1 protein (p.Asn509Ser). This variant is present in population databases (rs782158792, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of adrenoleukodystrophy (Invitae). ClinVar contains an entry for this variant (Variation ID: 458633). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCD1 protein function with a positive predictive value of 95%. This variant disrupts the p.Asn509 amino acid residue in ABCD1. Other variant(s) that disrupt this residue have been observed in individuals with ABCD1-related conditions (PMID: 14767898, 16415970), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV002395316 SCV002709654 uncertain significance Inborn genetic diseases 2017-11-10 criteria provided, single submitter clinical testing The p.N509S variant (also known as c.1526A>G), located in coding exon 6 of the ABCD1 gene, results from an A to G substitution at nucleotide position 1526. The asparagine at codon 509 is replaced by serine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Revvity Omics, Revvity RCV003488661 SCV004238403 likely pathogenic not provided 2023-03-10 criteria provided, single submitter clinical testing
Natera, Inc. RCV000534849 SCV002084643 uncertain significance Adrenoleukodystrophy 2020-10-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.